Severe Acute Exacerbation After Cessation of Nucleos(t)ide Analog for Chronic Hepatitis B: A Real-World Study of Routine Practice.

There is an ongoing debate as to whether patients with chronic hepatitis B (CHB) may discontinue nucleos(t)ide analogue (NA) therapy before seroclearance of hepatitis B surface antigen (HBsAg).1 Whereas treatment discontinuation may facilitate HBsAg seroclearance and avoid indefinite drug exposure,2 reactivation of viral replication almost always follows treatment cessation and frequently leads to clinical flares.3 In patients who encounter withdrawal flares, severe acute exacerbation (SAE) could occur with fatal consequences.4 Quantitative knowledge about the risk of SAE is imperative to inform the debate and also the practice.

Using SHERPA to predict human error on the maritime SAR helicopter hoist task.

In the realm of air-maritime SAR missions, technical errors are relatively rare compared to human errors due to the multifaceted nature of these missions that standard checklists may not fully encompass. Thus, prioritizing pilot training and implementing a systematic approach are vital to mitigate pilot errors in SAR missions. To mitigate and predict human errors during maritime SAR helicopter hoist tasks, SHERPA methodology is applied in this study. This analysis uncovered a comprehensive total of 54 potential errors, most applicable to countries utilizing rescue aircraft similar to those in Taiwan. The errors identified in this analysis suggest opportunities for enhancing the design of maritime SAR helicopter hoisting tasks through the application of SHERPA, with the potential to decrease their occurrence in the future.